Human herpesvirus 8 infection

Summary

Human herpesvirus 8 infection (MONDO:0005187) is a disease and 2 clinical trials. Top therapeutic interventions include darunavir, dolutegravir, and ritonavir. A subtype of Herpesviridae infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	human herpesvirus 8 infection
Mondo ID	MONDO:0005187
EFO	EFO:0002612
NCIT	C39291
UMLS	C1512508
MedGen	268211
Is cancer (heuristic)	no

Also known as: HHV8 infection · Human Herpes Virus 8 infection · Human Herpesvirus 8 infection

Disease family

This is a subtype of Herpesviridae infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › viral infectious disease › primary viral infectious disease › Herpesviridae infectious disease › human herpesvirus 8 infection

Related subtypes (7): herpetic gastritis, herpes simplex infectious disease, Epstein-Barr virus infection, cytomegalovirus infection, varicella zoster infection, roseolovirus infectious disease, congenital herpes virus infection

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE4	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04183738	PHASE4	WITHDRAWN	Inflammation and Co-Infections in D²EFT
NCT05081141	Not specified	RECRUITING	HHV8 and Solid Organ Transplantation

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DARUNAVIR	4	3
DOLUTEGRAVIR	4	1
RITONAVIR	4	1
CHEMBL4741920	0	1